Physician profile
Daniel Rossignol
NPI 1821076431
$548.99
in general payments reported to CMS, 2019-2025
11 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $40.21 · 2021: $98.07 · 2022: $76.27 · 2023: $53.75 · 2024: $13.40 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $197 · Education: $13.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $197.30 |
| Education | $13.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $143.55 | 2025 | Qelbree |
| Grifols USA, LLC | $120.88 | 2019-2023 | Xembify |
| Nestle Healthcare Nutrition INC. | $73.72 | 2021 | |
| Shire North American Group INC | $53.16 | 2019 | |
| Neurelis, INC. | $34.23 | 2022-2024 | Valtoco |
| Cranial Technologies, INC | $30.89 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.94 | 2023 | Cuvitru |
| Vivus LLC | $24.35 | 2021 | |
| Abbvie INC. | $19.27 | 2019 | |
| Csl Behring | $15.35 | 2019 | |
| Travere Therapeutics, INC. | $8.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Rossignol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.